Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents

Journal of Medicinal Chemistry

Volumn 41, Issue 23, 1998, Pages 4556-4566

  Aicher, Thomas D ^a   Balkan, Bork ^a   Bell, Philip A ^a   Brand, Leonard J ^a   Cheon, S H ^a   Deems, Rhonda O ^a   Fell, Jay B ^a   Fillers, William S ^a   Fraser, James D ^a   Gao, Jiaping ^a   Knorr, Douglas C ^a   Kahle, Gerald G ^a   Leone, Christina L ^a   Nadelson, Jeffrey ^a   Simpson, Ronald ^a   Smith, Howard C ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 CHLOROPHENOXY)METHYL] 7ALPHA (3,4 DICHLOROPHENYL)TETRAHYDROPYRROLO[2,1 B]OXAZOL 5(6H) ONE; ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CONFORMATION; DRUG EFFECT; DRUG SYNTHESIS; GLUCOSE UTILIZATION; HYPOGLYCEMIA; MALE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MUSCLES; OXAZOLES; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 15144342065     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9803121     Document Type: Article

References (32)

1. Presented in part at the 214th American Chemical Society Meeting, Las Vegas, NV, 1997; Abstr. 214 MEDI 221 and 221a.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998, 21, S5-19.
3. Roman, S. H.; Harris, M. I. Management of Diabetes Mellitus From a Public Health Perspective. Endocrinol. Metab. Clin. N. Am. 1997, 26.3, 443-474.
4. Isley, W. L. Treatment of Non-Insulin-Dependent Diabetes Mellitus. Drugs Today 1990, 26, 59-72.
5. Horton, E. S. Exercise and Physical Training. Diabetes / Metab. Rev. 1986, 2, 1-17.
6. Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977-986.
7. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 1998, 21, S88-90.
8. Ohkubo, Y.; Kishikawa, H.; Araki, E.; Miyata, T.; Isami, S.; Motoyoshi, S.; Kpjima, Y.; Furugoshi, N.; Shichiri, M. Intensive Insulin Therapy Prevents the Progression of Diabetic Microvascular Complications in Japanese Patients with Non-Insulin-Dependent Diabetes Mellitus: A Randomized Prospective 6-Year Study. Diabetes Res. Clin. Pract. 1995, 28, 103-117.
9. (a) Bogardus, C.; Lillioja, S.; Howard, B. V.; Reaven, G.; Mott, D. Relationship Between Insulin Secretion, Insulin Action, and Fasting Plasma Glucose Concentration in Non-Diabetic and Non-Insulin Dependent Diabetic Subjects. J. Clin. Invest. 1984, 74, 1238-1246.
10. (b) Reaven, G. M. Role of Insulin Resistance in Human Disease. Diabetes 1988, 37, 1595-1607.
11. (c) Stout, R. W. Overview of the Association between Insulin and Atherosclerosis. Metabolism 1985, 34 (Suppl. 1), 7-12.
12. (d) Stout, R. W. Insulin and Atheroma- An Update. Lancet 1987, 1, 1077-1079.
13. Ducimetiere, P.; Eschwege, E.; Papoz, L.; Richard, J. L.; Claude, J. R.; Rosselin, G. Relationship of Plasma Insulin Levels to the Incidence of Myocardial Infarction and Coronary Heart Disease Mortality in a Middle-aged Population. Diabetologia 1980, 19, 205-210.
14. Fuller, J. H.; Shipley, M. J.; Rose, G.; Jarret, R. J.; Keen, H. Coronary-Heart-Disease Risk and Impaired Glucose Tolerance. Lancet 1980, 1, 1373-1376.
15. National Diabetes Care Group. Diabetes in America; National Institutes of Health: Bethesda, MD, 1985.
16. Luft, D.; Schmulling, R. M.; Eggstein, M. Lactic Acidosis in Biguanide-Treated Diabetics: A Review of 330 Cases. Diabetologia 1978, 14, 75-87.
17. De Fronzo, R. A.; Goodman, A. M.; Multicenter Metformin Study Group. Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1995, 333, 541-549.
18. (a) Bailey, C. J. Biguanides and NIDDM. Diabetes Care 1992, 15, 773-784.
19. (b) Bell, P. M.; Hadden, D. R. Metformin. Endocrinol. Metab. Clin. N. Am. 1997, 26.3, 523-537.
20. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-668.
21. (a) Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H. Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob / ob mice and Zucker Fatty Rats. Diabetes 1988, 37, 1549-1558.
22. (b) Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R. Ciglitazone, a New Hypoglycemic Agent. 1. Studies in ob / ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic rats. Diabetes 1983, 32, 830-838.
23. (c) Iwamoto, Y.; Kuzuya, T.; Matsuda, A.; Awata, T.; Kumakura, S.; Inooka, G.; Shiraishi, I. Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients With NIDDM. Diabetes Care 1991, 14, 1083-1086.
24. (d) Henry, R. R. Thiazolidinediones. Endocrinol. Metab. Clin. N. Am. 1997, 26.3, 553-573.
25. Clancy, B. M.; Czech, M. P. Hexose Transport Stimulation and Membrane Redistribution of Glucose Transporter Isoforms in Response to Cholera Toxin, Dibutyryl Cyclic AMP, and Insulin in 3T3-L1 Adipocytes. J. Biol. Chem. 1990, 265, 12434-12443.
26. Sandoz merged with Ciba-Geigy to form Novartis on Jan 1, 1997.
27. Liu, K.-C.; Shelton, B. R.; Howe, R. K. A Particularity Convenient Preparation of Benzohydroximinoyl Chlorides (Nitrile Oxide Precursors). J. Org. Chem. 1980, 45, 3916-3918.
28. Modeling studies were performed with SYBYL 6.3 available from TRIPOS Associates, St. Louis, MO, 1993, using Gasteiger-Huckel charges and the consistent valence force field supplied with the SYBYL package. A systematic search for local minima was conducted. In each of the accessible local minima (<1.0 kcal above the global minima), the nearly coplanar arrangement of these seven atoms was observed.
29. Lipinski, C. A.; Lombarde, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
30. The clog P of this series was calculated using Moriguchi's method; see: Moriguchi, I.; Hirono, S.; Liu, Q.; Nakagome, Y.; Matsushita, Y. Simple Method of Calculating Octanol/Water Partition Coefficient. Chem. Pharm. Bull. 1992, 40, 127-130.
31. Bergman, R. N.; Ider, Y. Z.; Bowden, C. R.; Cobelli, C. R. Quantitative Estimation of Insulin Sensitivity. Am. J. Physiol. 1979, 236, E667-677.
32. Deems, R.; Balkan, B.; Bell, P.; Burkey, B.; Cheon, H.; Filiers, W.; Foley, J. Pharmacology of SDZ PGU 693, a Novel Glucose Utilization Enhancer/Insulin Sensitizer. Diabetes 1997, 46, 153A.